Abstract
Although most CD4+CD25+ regulatory T (Treg) cells develop in the thymus (i.e., natural Treg or nTreg), accumulating evidence suggests that they can also develop in the periphery (adaptive/induced Treg or iTreg). Both types of cells are functionally associated with the expression of Foxp3, a transcription factor that is constitutively expressed in nTreg cells and inducible during iTreg cell generation from CD4+CD25 – T lymphocytes. Multiple factors are involved in the generation and function of Treg cells, but a major role seems to be played by indoleamine 2,3-dioxygenase (IDO). IDO can both deplete tryptophan in local tissue microenvironments and generate immunoregulatory catabolites, known as kynurenines. Tryptophan starvation and presence of kynurenines can induce the conversion of naïve CD4+CD25 – T cells into highly suppressive CD4+CD25+Foxp3+ Treg cells. In turn, Treg cells induce IDO in dendritic cells (DCs) and convert inflammatory into regulatory DCs, which can further expand the Treg cell compartment by tryptophan catabolism. Evidence suggests that the modulation of IDO activity favors the interconversion between Treg cells and T helper type 17 (TH17) inflammatory cells. Thus, in the periphery, tolerogenic immune responses mediated by Treg cells can be induced and amplified by IDO, a tryptophan catabolizing enzyme that also contributes to the plasticity of the Treg cell lineage.
Keywords: Regulatory T cells, Dendritic Cells, IDO, Tryptophan catabolism, Amino acid starvation, Kynurenines, CD4+CD25+ regulatory T (Treg) cells, Foxp3, lymphocytes, tryptophan
Current Medicinal Chemistry
Title: Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Volume: 18 Issue: 15
Author(s): F. Fallarino and U. Grohmann
Affiliation:
Keywords: Regulatory T cells, Dendritic Cells, IDO, Tryptophan catabolism, Amino acid starvation, Kynurenines, CD4+CD25+ regulatory T (Treg) cells, Foxp3, lymphocytes, tryptophan
Abstract: Although most CD4+CD25+ regulatory T (Treg) cells develop in the thymus (i.e., natural Treg or nTreg), accumulating evidence suggests that they can also develop in the periphery (adaptive/induced Treg or iTreg). Both types of cells are functionally associated with the expression of Foxp3, a transcription factor that is constitutively expressed in nTreg cells and inducible during iTreg cell generation from CD4+CD25 – T lymphocytes. Multiple factors are involved in the generation and function of Treg cells, but a major role seems to be played by indoleamine 2,3-dioxygenase (IDO). IDO can both deplete tryptophan in local tissue microenvironments and generate immunoregulatory catabolites, known as kynurenines. Tryptophan starvation and presence of kynurenines can induce the conversion of naïve CD4+CD25 – T cells into highly suppressive CD4+CD25+Foxp3+ Treg cells. In turn, Treg cells induce IDO in dendritic cells (DCs) and convert inflammatory into regulatory DCs, which can further expand the Treg cell compartment by tryptophan catabolism. Evidence suggests that the modulation of IDO activity favors the interconversion between Treg cells and T helper type 17 (TH17) inflammatory cells. Thus, in the periphery, tolerogenic immune responses mediated by Treg cells can be induced and amplified by IDO, a tryptophan catabolizing enzyme that also contributes to the plasticity of the Treg cell lineage.
Export Options
About this article
Cite this article as:
Fallarino F. and Grohmann U., Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions, Current Medicinal Chemistry 2011; 18 (15) . https://dx.doi.org/10.2174/092986711795656027
DOI https://dx.doi.org/10.2174/092986711795656027 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Transient Focal Lesions in the Splenium of the Corpus Callosum with Restricted Diffusion: An Enigma
Current Medical Imaging Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?
Current Molecular Medicine CRF Receptor Antagonists: Utility in Research and Clinical Practice
Current Medicinal Chemistry Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Exploiting Microglial Functions for the Treatment of Glioblastoma
Current Cancer Drug Targets Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy 3D-Pharmacophere Models for CC Chemokine Receptor 1 Antagonists
Medicinal Chemistry Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets The Clinical Potential of Worms and their Products in Treating Inflammatory Diseases
Current Immunology Reviews (Discontinued) Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design Immune Stimulatory Strategies for the Prevention and Treatment of Asthma
Current Pharmaceutical Design Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design